
Astellas collaborates with Proteostasis on UPR candidates in possible $1.2bn deal
Executive Summary
Proteostasis Therapeutics Inc. (mostly focused on orphan and neurodegenerative diseases caused by defects in protein folding, trafficking, and clearance) and Astellas Pharma Inc. will research and develop therapeutic candidates that modulate the unfolded protein response (UPR) pathway.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- Genomics-Proteomics
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Includes Equity
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com